Live Breaking News & Updates on Nyu Langone X27s Perlmutter Cancer Center

Stay updated with breaking news from Nyu langone x27s perlmutter cancer center. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr Weber on the Background of the KEYNOTE-942 Trial in High-Risk Melanoma

Jeffrey S. Weber, MD, PhD, discusses the background for the KEYNOTE-942 trial, which was conducted in resected high-risk melanoma. ....

Jeffreys Weber , Grossman School Of Medicine , Melanoma Research Program , Langone Perlmutter Cancer Center , York University , New York University , Isaac Perlmutter Professor , Nyu Langone X27s Perlmutter Cancer Center , Onclive Tv , Skin Cancer ,

Dr D'Abreo on Patient Consideration When Choosing Treatments in HER2+ Breast Cancer

Nina D'Abreo, MD, discusses the importance of considering a patient’s medical history and preferences when deciding on a treatment course in HER2-positive breast cancer and highlights the important role of surgeons within breast cancer treatment.
....

Nina Dabreo , York University Grossman School Of Medicine , Perlmutter Cancer Center , Department Of Medicine , Division Of Hematology , Ninad Abreo , New York University Grossman School , Medical Oncology , Nyu Langone X27s Perlmutter Cancer Center , Onclive Tv , Neoadjuvant Her2 , Breast Cancer ,

Dr Wise on the Impact of Genetic Testing on Patient Outcomes in Prostate Cancer

David R. Wise, MD, PhD, discusses his presentation from an OncLive® State of the Science Summit™ on prostate cancer, during where he discussed the treatment of patients with metastatic castration-resistant prostate cancer. ....

Department Of Urology , Department Of Medicine , Langone Health Perlmutter Cancer Center , Grossman School Of Medicine , Langone Health , Genitourinary Medical Oncology , Perlmutter Cancer Center , Science Summit , Nyu Langone X27s Perlmutter Cancer Center , Onclive Tv , Prostate Cancer ,

Dr D'Abreo on the Evolution of ADC Use in the HER2+ Breast Cancer Treatment Landscape

Nina D'Abreo, MD, discusses the evolution of antibody-drug conjugates in the treatment of patients with HER2-low or HER2-positive breast cancer.
....

Nina Dabreo , Perlmutter Cancer Center , York University Grossman School Of Medicine , Department Of Medicine , Division Of Hematology , Ninad Abreo , New York University Grossman School , Medical Oncology , Nyu Langone X27s Perlmutter Cancer Center , Onclive Tv , Neoadjuvant Her2 ,

Dr Novik on Emergent Treatment Options in ER+ Breast Cancer

Yelena Novik, MD, discusses advancements and emerging trends that have been seen in the treatment of patients with advanced estrogen-receptor–positive breast cancer, citing clinical trials that have helped push the treatment armamentarium forward.
....

Yelena Novik , Department Of Medicine , Langone Health , Grossman School Of Medicine , York University , New York University , Grossman School , Science Summit , Nyu Langone X27s Perlmutter Cancer Center , Onclive Tv , Breast Cancer ,